Clovis Oncology, Inc. (NASDAQ:CLVS) – Investment analysts at Oppenheimer Holdings issued their Q2 2017 earnings per share estimates for Clovis Oncology in a research report issued to clients and investors on Thursday. Oppenheimer Holdings analyst L. Cann forecasts that the biopharmaceutical company will post earnings of ($1.18) per share for the quarter. Oppenheimer Holdings currently has a “Market Perform” rating on the stock. Oppenheimer Holdings also issued estimates for Clovis Oncology’s Q3 2017 earnings at ($1.13) EPS, Q4 2017 earnings at ($0.87) EPS, Q1 2018 earnings at ($0.67) EPS, Q2 2018 earnings at ($0.53) EPS, Q3 2018 earnings at ($0.53) EPS, Q4 2018 earnings at ($0.45) EPS, FY2018 earnings at ($2.17) EPS, FY2019 earnings at $2.07 EPS, FY2020 earnings at $3.55 EPS and FY2021 earnings at $4.97 EPS.

CLVS has been the topic of several other research reports. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $111.00 target price (up previously from $72.00) on shares of Clovis Oncology in a research report on Tuesday, June 20th. Bank of America Corporation cut their price objective on Clovis Oncology from $103.00 to $75.00 and set a “buy” rating on the stock in a research report on Tuesday, June 20th. Janney Montgomery Scott raised Clovis Oncology from a “neutral” rating to a “buy” rating in a research report on Tuesday, June 20th. Morgan Stanley reissued an “overweight” rating and issued a $79.00 price objective on shares of Clovis Oncology in a research report on Tuesday, June 20th. Finally, Cann assumed coverage on Clovis Oncology in a research report on Thursday. They issued a “market perform” rating on the stock. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Clovis Oncology presently has an average rating of “Buy” and a consensus price target of $72.40.

Earnings History and Estimates for Clovis Oncology (NASDAQ:CLVS)

TRADEMARK VIOLATION WARNING: “Clovis Oncology, Inc. (CLVS) to Post Q2 2017 Earnings of ($1.18) Per Share, Oppenheimer Holdings Forecasts” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/06/26/clovis-oncology-inc-clvs-to-post-q2-2017-earnings-of-1-18-per-share-oppenheimer-holdings-forecasts.html.

Shares of Clovis Oncology (NASDAQ:CLVS) opened at 95.00 on Monday. The company has a 50-day moving average price of $56.20 and a 200-day moving average price of $56.21. The company’s market cap is $4.25 billion. Clovis Oncology has a 1-year low of $11.57 and a 1-year high of $96.70.

Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings results on Wednesday, May 3rd. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.10. The business had revenue of $7.05 million during the quarter, compared to the consensus estimate of $6.04 million.

In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction on Monday, April 17th. The stock was sold at an average price of $56.02, for a total value of $168,060.00. Following the sale, the insider now directly owns 206,583 shares in the company, valued at $11,572,779.66. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 9,000 shares of company stock worth $495,690. Corporate insiders own 17.40% of the company’s stock.

Several hedge funds have recently modified their holdings of CLVS. FMR LLC raised its stake in shares of Clovis Oncology by 271.4% in the first quarter. FMR LLC now owns 1,816,859 shares of the biopharmaceutical company’s stock valued at $115,679,000 after buying an additional 1,327,703 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Clovis Oncology by 10,143.6% in the first quarter. Wellington Management Group LLP now owns 1,331,669 shares of the biopharmaceutical company’s stock valued at $84,788,000 after buying an additional 1,318,669 shares during the last quarter. State Street Corp raised its stake in shares of Clovis Oncology by 93.7% in the fourth quarter. State Street Corp now owns 2,141,663 shares of the biopharmaceutical company’s stock valued at $95,131,000 after buying an additional 1,035,917 shares during the last quarter. Alliancebernstein L.P. raised its stake in shares of Clovis Oncology by 1,538.0% in the first quarter. Alliancebernstein L.P. now owns 754,122 shares of the biopharmaceutical company’s stock valued at $48,015,000 after buying an additional 708,082 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Clovis Oncology by 25.3% in the first quarter. Vanguard Group Inc. now owns 3,285,195 shares of the biopharmaceutical company’s stock valued at $209,169,000 after buying an additional 662,969 shares during the last quarter. Hedge funds and other institutional investors own 97.55% of the company’s stock.

About Clovis Oncology

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.